ARTICLES BY RONALD A. RADER
The “New Normal”: Changing Perceptions on Bioprocess Intensification and Continuous Bioprocessing3/1/2021
Process intensification and continuous bioprocessing are concepts with inconsistent definitions. What's included often varies greatly and, in some ways, has become more about aspirational goal-setting than actual innovation adoption. Here, BioPlan Associates assesses the changing perspectives of 122 bioprocess decision-makers.
Bioprocessing Year In Review: 11 Key Trends Accelerated By COVID-1912/11/2020
Despite the morbidity, deaths, and terrible societal disruptions associated with the COVID-19 pandemic, 2020 will have created something of a positive outcome for the bioprocessing sector.
COVID-19’s Impact On Bioprocessing: Insights From Industry Leaders8/5/2020
We interviewed 26 biopharma senior executives regarding how they are handling the crisis and its long-term impact on their operations. We found the pandemic has begun to catalyze and accelerate a number of significant changes, including many preexisting trends.
Biosimilar Pipeline Experiencing 12% Annual Growth: A Progress Update3/26/2020
This article compares aspects of the biosimilar development pipeline and related market evolution since 2013, including what has and hasn’t changed.
Biosimilars Pipeline Shows Remarkable, Sustained Growth3/7/2019
The biosimilars pipeline is progressing rapidly and continues to grow, with more products and more organizations involved. This article reviews the current biosimilars development pipeline and progress.
Top Trends In The Biopharmaceutical Industry And Bioprocessing For 201912/18/2018
This article presents trends and findings from a survey and study of 222 responsible individuals at biopharmaceutical manufacturers and CMOs in 22 countries, as well as over 130 direct suppliers of materials, services, and equipment to this industry.
Biosimilars Pipeline Analysis: Many Products, More Competition Coming7/26/2016
Our discussion of biosimilars in this article will center on developed-market GMP biosimilars. In the European market alone, biosimilars already are a multibillion-dollar business, and one that is rapidly growing.